Pfizer's 6% Split: Specialty Care Is Saving the Story, but Primary Care Still Caps the Rebound

Pfizer's market split reflects two portfolios, not two verdicts

Pfizer is trading like a company the market still has not decided how to price.

Over the last month, shares have lost about 4.5% and underperformed the S&P 500. That looks less like a reaction to a bad quarter and more like hesitation around an incomplete story. In Q1, Pfizer delivered adjusted EPS of 75 cents versus 71 cents expected and revenue of $14.45 billion versus $13.82 billion expected. So the stock is not punting on execution. It is still questioning durability.

The better-growth argument is getting stronger

The improving side of the story is real. Higher revenues for Padcev, Eliquis, oncology biosimilars and others made up for the decline in sales of COVID products, Comirnaty and Paxlovid, and Sales of non-COVID products rose 7%. Within that, Specialty Care sales rose 8% and Sales of Oncology rose 7%. That weakens the simplest bear case that Pfizer is still living off old legacy revenue with nothing else materializing.

The problem is that the older part of the portfolio is still large enough to matter. The Primary Care segment declined 6% operationally, and that larger bucket is still holding back the broader growth profile. Bears can stay constructive on Specialty Care and Oncology and still argue the stock is capped as long as Primary Care remains soft.

Specialty Care is improving the quality of Pfizer's growth

What changed this time is not the headline top- and bottom-line result. It is the mix behind it.

Mid-single-digit growth is no longer coming from one place

In the last quarter, Specialty Care sales rose 8%, Sales of Oncology rose 7%, and Sales in the Hospital and Biosimilars segment rose 10%. That matters because it gives bulls a more credible argument: Pfizer is not relying on the same legacy mix it relied on two years ago. Total revenue reached $14.45 billion, up 5%, while several core franchises are still expanding. When growth broadens, investors usually give the company more credit.

There is also a geographic signal. U.S. revenues rose 4% while International revenues declined 1% on an operational basis. That suggests the healthier mix is showing up in the company's most closely watched market, not hiding in fragmented international residuals.

If the next few quarters confirm this mix shift, investors can keep moving Pfizer from former COVID giant toward a more broad-based pharma profile. The watchpoint is straightforward: if Specialty Care, Oncology, and Hospital and Biosimilars keep compounding while the legacy drag fades, the valuation case can improve. If not, skepticism will return quickly.

Primary Care softness is still the cleanest bear-case trigger

This is where the rebound thesis can break fastest: not in a flashy miss, but in another quarter where the same segmentation problem repeats. The Primary Care segment declined 6% operationally, while Pfizer's overall revenue increased only 2% on an operational basis. The good news is real, but it is still being pulled back by a larger legacy bucket.

COVID decay is still visible inside Primary Care

The pressure is still tied to COVID aftermath. the COVID vaccine and antiviral pill continued to drag on results. That does not automatically invalidate the recovery story, but it does give investors a reason to stay cautious about how durable the transition really is.

Bulls can fairly point out that the non-COVID portfolio is growing and that newer or acquired assets are doing more of the heavy lifting. But that does not remove the near-term risk. Pfizer also has 35 Phase 1 candidates, which shows the pipeline is active. It also shows that pipeline hope is still early-stage support, not a near-term pricing remedy if Primary Care stays soft.

What would change the stock's verdict

The next report matters less as a binary beat-or-miss event and more as a test of portfolio breadth. Does Pfizer keep beating expectations while showing that its better assets are becoming large enough to outweigh the market's old anchors?

The setup is more investable than it looked a month ago because the stock lost about 4.5% over the last month even after beating on both EPS and revenue. In plain English, investors are giving credit for execution but still withholding credit for durability. That gap is where a rebound can happen. The dividend helps keep the story on the radar: the board has set the second-quarter 2026 cash dividend at $0.43 per share, and yield support can matter when the growth narrative is still being debated.

What to watch into the next report

• Whether the Primary Care decline remains mostly a COVID story or starts reflecting broader portfolio weakness.
• Whether Specialty Care, Oncology, and Hospital and Biosimilars keep growing fast enough to offset that legacy softness.
• Whether the stock starts rewarding incremental improvement, which would suggest sentiment was primed for another disappointment rather than the fundamentals turning dramatically better.